Ligozzi Marco, Bernini Cinzia, Bonora Maria Grazia, De Fatima Maria, Zuliani Jessica, Fontana Roberta
Sezione di Microbiologia, Dipartimento di Patologia, Università di Verona, Strada le Grazie 8, 35100 Verona, Italy.
J Clin Microbiol. 2002 May;40(5):1681-6. doi: 10.1128/JCM.40.5.1681-1686.2002.
A study was conducted to evaluate the new VITEK 2 system (bioMérieux) for identification and antibiotic susceptibility testing of gram-positive cocci. Clinical isolates of Staphylococcus aureus (n = 100), coagulase-negative staphylococci (CNS) (n = 100), Enterococcus spp. (n = 89), Streptococcus agalactiae (n = 29), and Streptococcus pneumoniae (n = 66) were examined with the ID-GPC identification card and with the AST-P515 (for staphylococci), AST-P516 (for enterococci and S. agalactiae) and AST-P506 (for pneumococci) susceptibility cards. The identification comparison methods were the API Staph for staphylococci and the API 20 Strep for streptococci and enterococci; for antimicrobial susceptibility testing, the agar dilution method according to the procedure of the National Committee for Clinical Laboratory Standards (NCCLS) was used. The VITEK 2 system correctly identified to the species level (only one choice or after simple supplementary tests) 99% of S. aureus, 96.5% of S. agalactiae, 96.9% of S. pneumoniae, 92.7% of Enterococcus faecalis, 91.3% of Staphylococcus haemolyticus, and 88% of Staphylococcus epidermidis but was least able to identify Enterococcus faecium (71.4% correct). More than 90% of gram-positive cocci were identified within 3 h. According to the NCCLS breakpoints, antimicrobial susceptibility testing with the VITEK 2 system gave 96% correct category agreement, 0.82% very major errors, 0.17% major errors, and 2.7% minor errors. Antimicrobial susceptibility testing showed category agreement from 94 to 100% for S. aureus, from 90 to 100% for CNS, from 91 to 100% for enterococci, from 96 to 100% for S. agalactiae, and from 91 to 100% for S. pneumoniae. Microorganism-antibiotic combinations that gave very major errors were CNS-erythromycin, CNS-oxacillin, enterococci-teicoplanin, and enterococci-high-concentration gentamicin. Major errors were observed for CNS-oxacillin and S. agalactiae-tetracycline combinations. In conclusion the results of this study indicate that the VITEK 2 system represents an accurate and acceptable means for performing identification and antibiotic susceptibility tests with medically relevant gram-positive cocci.
开展了一项研究,以评估新型VITEK 2系统(生物梅里埃公司)对革兰氏阳性球菌的鉴定及抗生素敏感性检测能力。使用ID-GPC鉴定卡以及AST-P515(用于葡萄球菌)、AST-P516(用于肠球菌和无乳链球菌)和AST-P506(用于肺炎链球菌)药敏卡,对金黄色葡萄球菌(n = 100)、凝固酶阴性葡萄球菌(CNS)(n = 100)、肠球菌属(n = 89)、无乳链球菌(n = 29)和肺炎链球菌(n = 66)的临床分离株进行检测。鉴定的比较方法为:对葡萄球菌采用API Staph,对链球菌和肠球菌采用API 20 Strep;抗菌药物敏感性检测采用符合美国国家临床实验室标准委员会(NCCLS)程序的琼脂稀释法。VITEK 2系统能够将99%的金黄色葡萄球菌、96.5%的无乳链球菌、96.9%的肺炎链球菌、92.7%的粪肠球菌、91.3%的溶血葡萄球菌和88%的表皮葡萄球菌准确鉴定到种水平(仅一种选择或经过简单补充试验后),但对屎肠球菌的鉴定能力最差(正确鉴定率为71.4%)。90%以上的革兰氏阳性球菌在3小时内得到鉴定。根据NCCLS的断点,VITEK 2系统进行的抗菌药物敏感性检测的类别符合率为96%,极重大错误率为0.82%,重大错误率为0.17%, minor错误率为2.7%。抗菌药物敏感性检测显示,金黄色葡萄球菌的类别符合率为94%至100%,CNS为90%至100%,肠球菌为91%至100%,无乳链球菌为96%至100%,肺炎链球菌为91%至100%。导致极重大错误的微生物-抗生素组合为CNS-红霉素、CNS-苯唑西林、肠球菌-替考拉宁和肠球菌-高浓度庆大霉素。观察到CNS-苯唑西林和无乳链球菌-四环素组合出现重大错误。总之,本研究结果表明,VITEK 2系统是对医学上相关革兰氏阳性球菌进行鉴定和抗生素敏感性检测的一种准确且可接受的方法。